Mechanism of radiosensitization by the Chk1/2 inhibitor AZD7762 involves abrogation of the G2 checkpoint and inhibition of homologous recombinational DNA repair

Cancer Research

Volumn 70, Issue 12, 2010, Pages 4972-4981

  Morgan, Meredith A ^a   Parsels, Leslie A ^a   Zhao, Lili ^b   Parsels, Joshua D ^a   Davis, Mary A ^a   Hassan, Maria C ^a   Arumugarajah, Sankari ^a   Hylander Gans, Linda ^c   Morosini, Deborah ^c   Simeone, Diane M ^a   Canman, Christine E ^a   Normolle, Daniel P ^a   Zabludoff, Sonya D ^c   Maybaum, Jonathan ^a   Lawrence, Theodore S ^a  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF MICHIGAN   (United States)

^c ASTRAZENECA   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ATM PROTEIN; ATR PROTEIN; AZD 7762; CHECKPOINT KINASE 1; CHECKPOINT KINASE 2; GEMCITABINE; HISTONE H2AX; PROTEIN SERINE THREONINE KINASE INHIBITOR; PROTEIN TYROSINE PHOSPHATASE; RAD51 PROTEIN; RADIOSENSITIZING AGENT; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ARTICLE; CANCER RADIOTHERAPY; CELL CYCLE ARREST; CELL CYCLE G2 PHASE; CONTROLLED STUDY; DNA REPAIR; DRUG EFFICACY; ENZYME PHOSPHORYLATION; HOMOLOGOUS RECOMBINATION; IN VITRO STUDY; MOUSE; NONHUMAN; PANCREAS CANCER; PRIORITY JOURNAL; PROTEIN EXPRESSION; RADIOSENSITIZATION; TUMOR VOLUME;

ADENOCARCINOMA; ANIMALS; BLOTTING, WESTERN; CELL LINE, TUMOR; DEOXYCYTIDINE; DNA DAMAGE; DNA REPAIR; DRUG THERAPY, COMBINATION; FLOW CYTOMETRY; FLUORESCENT ANTIBODY TECHNIQUE; G2 PHASE; GAMMA RAYS; HUMANS; IMMUNOBLOTTING; IMMUNOENZYME TECHNIQUES; MICE; MICE, INBRED NOD; MICE, SCID; PANCREATIC NEOPLASMS; PROTEIN KINASE INHIBITORS; PROTEIN KINASES; PROTEIN-SERINE-THREONINE KINASES; RAD51 RECOMBINASE; RADIATION-SENSITIZING AGENTS; RECOMBINATION, GENETIC; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; THIOPHENES; UREA; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 77953770987     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-09-3573     Document Type: Article

References (48)

1. In: Ries LAG, Melbert DKM, Stinchcomb DG, et al, editors. SEER Cancer Statistics Review, 1975-2005. Bethesda (MD): National Cancer Institute; 2008.
2. Loehrer PJ, Powell ME, Cardenes HR, et al. A randomized phase III study of gemcitabine in combination with radiation therapy versus gemcitabine alone in patients with localized, unresectable pancreatic cancer: E4201. J Clin Oncol 2008;26 (May 20 Suppl): Abstract 4506.
3. McGinn CJ, Zalupski MM, Shureiqi I, et al. Phase I trial of radiation dose escalation with concurrent weekly full-dose gemcitabine in patients with advanced pancreatic cancer. J Clin Oncol 2001;19:4202-8.
4. Morgan MA, Meirovitz A, Davis MA, Kollar LE, Hassan MC, Lawrence TS. Radiotherapy combined with gemcitabine and oxaliplatin in pancreatic cancer cells. Transl Oncol 2008;1:36-43.
5. Morgan MA, Parsels LA, Kollar LE, Normolle DP, Maybaum J, Lawrence TS. The combination of epidermal growth factor receptor inhibitors with gemcitabine and radiation in pancreatic cancer. Clin Cancer Res 2008;14:5142-9.
6. Liu Q, Guntuku S, Cui XS, et al. Chk1 is an essential kinase that is regulated by Atr and required for the G(2)/M DNA damage checkpoint. Genes Dev 2000;14:1448-59.
7. 2 checkpoints. Proc Natl Acad Sci U S A 2002;99:14795-800.
8. Sorensen CS, Hansen LT, Dziegielewski J, et al. The cell-cycle checkpoint kinase Chk1 is required for mammalian homologous recombination repair. Nat Cell Biol 2005;7:195-201.
9. Karnitz LM, Flatten KS, Wagner JM, et al. Gemcitabine-induced activation of checkpoint signaling pathways that affect tumor cell survival. Mol Pharmacol 2005;68:1636-44.
10. Carrassa L, Broggini M, Erba E, Damia G. Chk1, but not Chk2, is involved in the cellular response to DNA damaging agents: differential activity in cells expressing or not p53. Cell Cycle 2004;3:1177-81.
11. Hu B, Zhou XY, Wang X, Zeng ZC, Iliakis G, Wang Y. The radioresistance to killing of A1-5 cells derives from activation of the Chk1 pathway. J Biol Chem 2001;276:17693-8. (Pubitemid 37411321)
12. Janetka JW, Ashwell S, Zabludoff S, Lyne P. Inhibitors of checkpoint kinases: from discovery to the clinic. Curr Opin Drug Discov Dev 2007;10:473-86. (Pubitemid 47093131)
13. Zabludoff SD, Deng C, Grondine MR, et al. AZD7762, a novel checkpoint kinase inhibitor, drives checkpoint abrogation and potentiates DNA-targeted therapies. Mol Cancer Ther 2008;7:2955-66.
14. Tao Y, Leteur C, Yang C, et al. Radiosensitization by Chir-124, a selective CHK1 inhibitor: effects of p53 and cell cycle checkpoints. Cell Cycle 2009;8:1196-205.
15. Matthews DJ, Yakes FM, Chen J, et al. Pharmacological abrogation of S-phase checkpoint enhances the anti-tumor activity of gemcitabine in vivo. Cell Cycle 2007;6:104-10.
16. Blasina A, Hallin J, Chen E, et al. Breaching the DNA damage checkpoint via PF-00477736, a novel small-molecule inhibitor of checkpoint kinase 1. Mol Cancer Ther 2008;7:2394-404.
17. 2 checkpoint function in cancer cells with disrupted p53. J Natl Cancer Inst 1996;88:956-65.
18. Kortmansky J, Shah MA, Kaubisch A, et al. Phase I trial of the cyclin-dependent kinase inhibitor and protein kinase C inhibitor 7-hydroxystaurosporine in combination with fluorouracil in patients with advanced solid tumors. J Clin Oncol 2005;23:1875-84.
19. Fuse E, Kuwabara T, Sparreboom A, Sausville EA, Figg WD. Review of UCN-01 development: a lesson in the importance of clinical pharmacology. J Clin Pharmacol 2005;45:394-403. (Pubitemid 40490412)
20. Parry D, Shanhan F, Davis N, et al. Targeting the replication checkpoint with a potent and selective CHK1 inhibitor. Proceedings of the 100th Annual Meeting of the American Association for Cancer Research. 2009;50. Abstract number 2490.
21. Ashwell S, Zabludoff S. DNA damage detection and repair pathways - recent advances with inhibitors of checkpoint kinases in cancer therapy. Clin Cancer Res 2008;14:4032-7.
22. Bucher N, Britten CD. G2 checkpoint abrogation and checkpoint kinase-1 targeting in the treatment of cancer. Br J Cancer 2008;98:523-8. (Pubitemid 351214533)
23. Morgan MA, Parsels LA, Parsels JD, Mesiwala AK, Maybaum J, Lawrence TS. Role of checkpoint kinase 1 in preventing premature mitosis in response to gemcitabine. Cancer Res 2005;65:6835-42. (Pubitemid 41060722)
24. Arlander SJ, Eapen AK, Vroman BT, McDonald RJ, Toft DO, Karnitz LM. Hsp90 inhibition depletes Chk1 and sensitizes tumor cells to replication stress. J Biol Chem 2003;278:52572-7.
25. Morgan MA, Parsels LA, Parsels JD, Lawrence TS, Maybaum J. The relationship of premature mitosis to cytotoxicity in response to checkpoint abrogation and antimetabolite treatment. Cell Cycle 2006;5:1983-8. (Pubitemid 44435305)
26. Parsels LA, Morgan MA, Tanska DM, et al. Gemcitabine sensitization by checkpoint kinase 1 inhibition correlates with inhibition of a Rad51 DNA damage response in pancreatic cancer cells. Mol Cancer Ther 2009;8:45-54.
27. Lawrence TS. Ouabain sensitizes tumor cells but not normal cells to radiation. Int J Radiat Oncol Biol Phys 1988;15:953-8.
28. Fertil B, Dertinger H, Courdi A, Malaise EP. Mean inactivation dose: a useful concept for intercomparison of human cell survival curves. Radiat Res 1984;99:73-84. (Pubitemid 14095136)
29. Huang X, Halicka HD, Darzynkiewicz Z. Detection of histone H2AX phosphorylation on Ser-139 as an indicator of DNA damage (DNA double-strand breaks). Curr Protoc Cytom 2004;Chapter 7:Unit 7.27.
30. Hoy CA, Seamer LC, Schimke RT. Thermal denaturation of DNA for immunochemical staining of incorporated bromodeoxyuridine (BrdUrd): critical factors that affect the amount of fluorescence and the shape of BrdUrd/DNA histogram. Cytometry 1989;10:718-25.
31. Pierce AJ, Johnson RD, Thompson LH, Jasin M. XRCC3 promotes homology-directed repair of DNA damage in mammalian cells. Genes Dev 1999;13:2633-8.
32. Li C, Heidt DG, Dalerba P, et al. Identification of pancreatic cancer stem cells. Cancer Res 2007;67:1030-7.
33. Lindstrom MJ, Kunugi KA, Kinsella TJ. Global comparison of radiation and chemotherapy dose-response curves with a test for interaction. Radiat Res 1993;135:269-77.
34. Mailand N, Falck J, Lukas C, et al. Rapid destruction of human Cdc25A in response to DNA damage. Science 2000;288:1425-9.
35. Zhang YW, Otterness DM, Chiang GG, et al. Genotoxic stress targets human Chk1 for degradation by the ubiquitin-proteasome pathway. Mol Cell 2005;19:607-18.
36. Syljuasen RG, Sorensen CS, Nylandsted J, Lukas C, Lukas J, Bartek J. Inhibition of Chk1 by CEP-3891 accelerates mitotic nuclear fragmentation in response to ionizing Radiation. Cancer Res 2004;64:9035-40.
37. Ganzinelli M, Carrassa L, Crippa F, Tavecchio M, Broggini M, Damia G. Checkpoint kinase 1 down-regulation by an inducible small interfering RNA expression system sensitized in vivo tumors to treatment with 5-fluorouracil. Clin Cancer Res 2008;14:5131-41.
38. Han H, Bearss DJ, Browne LW, Calaluce R, Nagle RB, Von Hoff DD. Identification of differentially expressed genes in pancreatic cancer cells using cDNA microarray. Cancer Res 2002;62:2890-6.
39. Vispe S, Cazaux C, Lesca C, Defais M. Overexpression of Rad51 protein stimulates homologous recombination and increases resistance of mammalian cells to ionizing radiation. Nucleic Acids Res 1998;26:2859-64.
40. Maitra A, Kern SE, Hruban RH. Molecular pathogenesis of pancreatic cancer. Best Pract Res Clin Gastroenterol 2006;20:211-26.
41. Maacke H, Jost K, Opitz S, et al. DNA repair and recombination factor Rad51 is over-expressed in human pancreatic adenocarcinoma. Oncogene 2000;19:2791-5.
42. Frankenberg-Schwager M, Gebauer A, Koppe C, Wolf H, Pralle E, Frankenberg D. Single-strand annealing, conservative homologous recombination, nonhomologous DNA end joining, and the cell cycle-dependent repair of DNA double-strand breaks induced by sparsely or densely ionizing radiation. Radiat Res 2009;171:265-73.
43. Mladenov EV, Kalev PS, Anachkova BB. The complexity of double-strand break ends is a factor in the repair pathway choice. Radiat Res 2009;171:397-404.
44. Wang H, Wang X, Iliakis G, Wang Y. Caffeine could not efficiently sensitize homologous recombination repair-deficient cells to ionizing radiation-induced killing. Radiat Res 2003;159:420-5.
45. Wachters FM, van Putten JW, Maring JG, Zdzienicka MZ, Groen HJ, Kampinga HH. Selective targeting of homologous DNA recombination repair by gemcitabine. Int J Radiat Oncol Biol Phys 2003;57:553-62.
46. Lawrence TS, Chang EY, Hahn TM, Hertel LW, Shewach DS. Radiosensitization of pancreatic cancer cells by 2′,2′-difluoro-2′- deoxycytidine. Int J Radiat Oncol Biol Phys 1996;34:867-72.
47. Ahn JY, Schwarz JK, Piwnica-Worms H, Canman CE. Threonine 68 phosphorylation by ataxia telangiectasia mutated is required for efficient activation of Chk2 in response to ionizing radiation. Cancer Res 2000;60:5934-6.
48. Morgan MA, Parsels LA, Maybaum J, Lawrence TS. Improving gemcitabine-mediated radiosensitization using molecularly targeted therapy: a review. Clin Cancer Res 2008;14:6744-50.